Skip to main content

Vivos Therapeutics, Inc. (VVOS) Stock Forecast

Data as of Aug 7, 2026

Healthcare · Current price $0.33 (+1.30%)

Consensus Target
$2.13
Upside
+427.8%
Analysts
3
Rating
Buy(2.00)

Price Target Range

Low $1.75Consensus $2.13High $2.50
▲ Current $0.33

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

VVOS vs Sector & Market

MetricVVOSHealthcare AvgLarge Cap Avg
Analyst Rating2.002.252.42
Analyst Count3818
Target Upside+427.8%+16315.7%+17.2%
P/E Ratio-0.373.5936.06

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$31M$31M$31M3
2027-12-31$47M$52M$54M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-1.35$-1.28$-1.112
2027-12-31$0.00$0.00$0.000

Frequently Asked Questions

What is the analyst consensus for VVOS?

The consensus among 3 analysts covering Vivos Therapeutics, Inc. (VVOS) is Buy with an average price target of $2.13.

What is the highest price target for VVOS?

The highest analyst price target for VVOS is $2.50.

What is the lowest price target for VVOS?

The lowest analyst price target for VVOS is $1.75.

How many analysts cover VVOS?

3 analysts have issued ratings for Vivos Therapeutics, Inc. in the past 12 months.

Is VVOS a buy or sell right now?

Based on 3 analyst ratings, VVOS has a consensus rating of Buy (2.00/5) with a +427.8% upside to the consensus target of $2.13.

What are the earnings estimates for VVOS?

Analysts estimate VVOS will report EPS of $-1.28 for the period ending 2026-12-31, with revenue estimated at $31M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.